GSA Capital Partners LLP Sells 15,134 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

GSA Capital Partners LLP lessened its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 58.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,667 shares of the company’s stock after selling 15,134 shares during the quarter. GSA Capital Partners LLP’s holdings in Nurix Therapeutics were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Amalgamated Bank lifted its stake in shares of Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares during the period. GAMMA Investing LLC boosted its holdings in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after buying an additional 3,424 shares during the last quarter. International Assets Investment Management LLC grew its position in shares of Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after buying an additional 4,119 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after buying an additional 998 shares during the period.

Insider Activity

In other news, CFO Houte Hans Van sold 20,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the sale, the chief financial officer now directly owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. This represents a 39.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christine Ring sold 9,870 shares of Nurix Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.01, for a total value of $246,848.70. Following the transaction, the insider now owns 24,592 shares of the company’s stock, valued at $615,045.92. The trade was a 28.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,321 shares of company stock valued at $1,414,409. 7.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on NRIX shares. Royal Bank of Canada reduced their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Oppenheimer boosted their price target on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. Stephens restated an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research report on Monday, October 14th. HC Wainwright lifted their target price on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Truist Financial initiated coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price target for the company. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Nurix Therapeutics Trading Down 1.4 %

Shares of NRIX stock opened at $22.05 on Friday. The firm’s fifty day moving average price is $24.37 and its two-hundred day moving average price is $21.54. Nurix Therapeutics, Inc. has a 1 year low of $5.65 and a 1 year high of $29.56. The firm has a market capitalization of $1.56 billion, a P/E ratio of -7.58 and a beta of 2.20.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.